Oct 28, 2009 by Brian Orelli, PhDSaved by Emerging Markets. Sort Of.GlaxoSmithKline's top line looks good, but the bottom is what counts.
Oct 27, 2009 by Brian Orelli, PhDBack From the Dead: A Public OptionJust when things seemed to be going their way.
Oct 27, 2009 by Brian Orelli, PhDSmall Market, Small Acquisition, Still a Good MoveBioMarin does everything small.
Oct 27, 2009 by Brian Orelli, PhDPfizer's and Merck's Loss Is These Companies' GainToo busy integrating to take advantage of additional acquisitions.
Oct 23, 2009 by Brian Orelli, PhDNot 50% Growth, but We'll Take ItDouble-digit growth is still pretty good.
Oct 23, 2009 by Brian Orelli, PhDMerck-Schering Doesn't Look So GoodRevenue is stagnant; let's hope that pipeline pans out.
Oct 23, 2009 by Brian Orelli, PhDI Don't Need No Massive MergerPlavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
Oct 23, 2009 by Brian Orelli, PhDSwine Flu Doesn't Need to Save NovartisThe company is looking healthy all on its own.
Oct 22, 2009 by Brian Orelli, PhDThe Gift That Keeps on GivingManufacturing problems knock down Genzyme.
Oct 21, 2009 by Brian Orelli, PhDDouble-Digit Growth in a RecessionVirus-killing Gilead gets it done.
Oct 21, 2009 by Brian Orelli, PhDSlicing and Dicing Intuitive Surgical's QuarterNot the best we've seen, but still solid.
Oct 21, 2009 by Brian Orelli, PhDWhen Fundamentals Don't MatterIf Uncle Sam steps in, earnings suddenly lose importance.
